Introduction
Polymyalgia rheumatica is caused by an abnormal inflammatory process that develops in the tissues around the shoulders, neck, and hips, and in the blood vessels and immune signaling pathways that regulate inflammation. It is not caused by wear and tear alone, and it is not fully explained by a single trigger. Instead, the condition appears to arise when an aging immune system, genetic susceptibility, and external factors combine to produce persistent inflammation in structures near large joints. The main influences discussed in this article are immune dysregulation, genetic predisposition, age-related biological change, environmental exposures, and certain medical conditions that can activate or mimic the same inflammatory pathways.
Biological Mechanisms Behind the Condition
The core biological problem in polymyalgia rheumatica is inappropriate activation of the immune system. In a healthy person, inflammation is tightly controlled and turns off after an injury or infection has been dealt with. In polymyalgia rheumatica, inflammatory signaling appears to remain active for too long, especially in tissues around the proximal joints, such as the shoulder and pelvic girdles. This leads to pain, stiffness, and reduced mobility, but the underlying issue is the inflammatory state itself.
Several immune mechanisms are thought to contribute. Cells of the innate immune system, including macrophages and other inflammatory cells, become activated and release cytokines such as interleukin-6 and other pro-inflammatory mediators. These molecules increase inflammation in surrounding tissues and produce the generalized inflammatory response seen in the condition. At the same time, the adaptive immune system may also be altered, although polymyalgia rheumatica does not follow the exact pattern of classic autoimmune diseases. The inflammation is usually less about direct destruction of a single tissue and more about a diffuse inflammatory state involving bursae, tendons, and synovial structures.
Another important feature is the relationship between polymyalgia rheumatica and the walls of large and medium-sized arteries. The same immune activation that affects musculoskeletal tissues can overlap with vascular inflammation, which is why the condition is closely linked with giant cell arteritis in some patients. This suggests that polymyalgia rheumatica is part of a broader inflammatory spectrum rather than an isolated musculoskeletal disorder. Age-related changes in immune regulation, sometimes described as immunosenescence, may make this inflammatory pattern more likely by reducing the body’s ability to maintain immune balance.
Primary Causes of Polymyalgia Rheumatica
There is no single proven cause of polymyalgia rheumatica, but several main factors are strongly associated with its development. The first is immune system dysregulation. The condition seems to begin when inflammatory pathways become overactive without an obvious sustained injury. This abnormal immune response causes the release of cytokines that promote pain and stiffness in tissues around major joints. The inflammation also affects the way the body processes pain and movement, which is why symptoms can be severe even though imaging or structural damage may be limited.
A second major factor is age-related biological change. Polymyalgia rheumatica occurs mainly in older adults, typically after age 50 and most often much later in life. Aging affects immune surveillance, inflammatory control, and vascular function. With age, the immune system becomes more prone to low-grade chronic activation and less efficient at shutting down inflammatory responses. This makes it easier for a relatively minor trigger to create a prolonged inflammatory state. Age also changes connective tissue and the tissues around joints, which may make them more vulnerable to inflammatory irritation.
A third influence is the involvement of large-vessel inflammation. Although polymyalgia rheumatica is often thought of as a muscle condition, the primary issue is not a true muscle disease. Instead, inflammation may occur in periarticular tissues and in blood vessel walls, especially in patients who also develop giant cell arteritis. This vascular component helps explain why the condition can have systemic inflammatory features, including fatigue and raised inflammatory markers. The blood vessels and surrounding tissues become part of the inflammatory process, which broadens the symptom pattern beyond a single joint region.
Contributing Risk Factors
Genetic influences likely shape who develops polymyalgia rheumatica. The condition is more common in some populations, especially people of Northern European ancestry, suggesting that inherited differences in immune regulation matter. Certain human leukocyte antigen, or HLA, patterns have been linked to increased susceptibility. These genes help the immune system distinguish between normal tissue and potential threats. If these signaling systems are less finely tuned, the immune response may be more likely to become excessive or persist longer than it should. Genetics does not directly cause the condition on its own, but it can create a background of vulnerability.
Environmental exposures may also contribute, although no single exposure has been proved to cause polymyalgia rheumatica. Seasonal patterns in diagnosis and the tendency for some cases to appear after periods of infection have led researchers to suspect that environmental immune triggers may be involved. Viruses and other infectious agents can activate inflammatory pathways and potentially set off an immune response in someone who is already susceptible. The most plausible role of environmental triggers is not direct tissue damage, but stimulation of immune signaling that then becomes self-sustaining.
Infections are often discussed as possible contributors because they can transiently alter immune regulation. When the body responds to infection, cytokine production rises and immune cells become more active. In a person with underlying susceptibility, that response may fail to resolve properly. The result may be continued inflammation even after the initial infectious trigger has disappeared. This theory is consistent with the observation that polymyalgia rheumatica often appears without a clear ongoing cause once the inflammatory state has begun.
Hormonal changes may also matter, especially the decline in sex hormone levels that accompanies aging. Hormones influence immune activity, vascular tone, and connective tissue biology. As hormone levels change with age, the balance between pro-inflammatory and anti-inflammatory signals can shift. Although this is probably not a primary cause by itself, it may help explain why the disease emerges in later life and why immune responses become harder to regulate.
Lifestyle factors are less clearly causal, but they may influence baseline inflammation and vascular health. Smoking history, reduced physical activity, and overall metabolic health may shape how strongly the body responds to inflammatory stress. These factors do not appear to be direct causes in the way that genetics or immune aging are, but they can influence the biological environment in which polymyalgia rheumatica develops.
How Multiple Factors May Interact
Polymyalgia rheumatica is best understood as the result of interacting biological systems rather than a single isolated cause. A susceptible genetic background may establish a lower threshold for immune activation. Age-related changes in immune regulation may then reduce the body’s ability to turn off inflammatory responses. If an environmental trigger such as an infection occurs during this period, immune cells may become activated and begin producing cytokines that are not fully suppressed. Once this inflammatory cascade starts, it can affect tissues around the shoulders and hips and, in some cases, large blood vessels as well.
These interactions help explain why the disease can begin suddenly even in someone who seemed well beforehand. The immune system, vascular system, and connective tissues are all linked. Inflammation in one part of the system can influence the others through chemical signaling and altered circulation. The process is not necessarily driven by ongoing tissue injury; rather, the body’s own inflammatory mechanisms may become amplified and self-perpetuating.
Variations in Causes Between Individuals
The causes of polymyalgia rheumatica vary because people differ in genetic susceptibility, immune aging, and exposure history. Two people of the same age may have very different levels of risk depending on inherited immune traits, prior infections, and underlying vascular health. One person may develop the condition after a clear infectious illness, while another may have no identifiable trigger at all. This does not mean the disease is random; it means that the same final inflammatory pathway can be reached through different biological routes.
Age is especially important in shaping individual variation. In older adults, immune regulation becomes less stable, and this decline may be more pronounced in some people than in others. Pre-existing health status also matters because chronic diseases can influence inflammation and vascular function. A person with a stronger baseline inflammatory tendency may be more vulnerable to the immune shifts that lead to polymyalgia rheumatica. Environmental exposure history further modifies risk by determining how often the immune system has been activated over time.
Conditions or Disorders That Can Lead to Polymyalgia Rheumatica
Certain medical conditions are associated with the onset of polymyalgia rheumatica, either because they share inflammatory pathways or because they can trigger the same immune response. The most important related disorder is giant cell arteritis. This condition involves inflammation of medium and large arteries and has a close biological relationship with polymyalgia rheumatica. Some researchers view the two conditions as overlapping parts of a shared inflammatory spectrum. In people who develop both, the vascular inflammation may help drive the musculoskeletal symptoms.
Other inflammatory or autoimmune disorders may contribute indirectly by creating a general background of immune activation. When the immune system is already dysregulated, it may be easier for a polymyalgia rheumatica-like inflammatory pattern to emerge. Certain infections can also act as triggers by stimulating cytokines and immune cell activity. In these cases, the relationship is physiological rather than simple cause and effect: the condition may begin after the immune system is pushed into a heightened inflammatory state, especially if underlying susceptibility is present.
Because polymyalgia rheumatica is part of a broader inflammatory process, disorders that affect blood vessels, immune regulation, or connective tissue can alter the likelihood that it will appear. The key relationship is not that one disease directly transforms into another, but that several conditions can converge on the same inflammatory pathways and produce a similar clinical syndrome.
Conclusion
Polymyalgia rheumatica develops through a combination of immune dysregulation, aging-related changes in immune control, genetic susceptibility, and possible environmental or infectious triggers. Its biological basis lies in persistent inflammation affecting periarticular tissues and, in some cases, large blood vessels. The condition is not explained by a single cause, but by the interaction of several systems that become less capable of regulating inflammation with age. Understanding these mechanisms shows why the disease is most common in older adults, why it may appear suddenly, and why it is often linked with other inflammatory disorders. The causes of polymyalgia rheumatica are therefore best viewed as layered and interdependent, rather than simple or purely mechanical.